著者

中村 誓志 森田 恵美子 木村 貞恵 定本 裕美 上野 正嗣 岩井 礼子 生島 忍 広川 慶裕

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.34, no.10, pp.938-942, 2008 (Released:2010-02-07)

参考文献数

13

---

Scabies is a major form of dermatitis and in the second edition of clinical management guidelines for scabies drawn up by a committee of the Japanese Dermatological Association in 2007,ivermectin was recommended as a drug of choice for its treatment.Ivermectin had been approved as a treatment for scabies and launched in Japan in August 2006.On administering ivermection to 6 patients who developed scabies in our geriatric mental ward,3 of them subsequently developed hepatic function disorders.In order to investigate the cause of these disorders,we examined their weights,ages,drug interactions,and metabolism.We found that blood levels of ivermectin were easily affected by fat in the diet due to its liposolubility.In addition,since CYP3A4,an enzyme considered to be involved in the metabolism of ivermectin,may increase the toxicity of its metabolic products,we concluded that use of ivermectin should be reviewed.It is recommended that hepatic function tests are carried out a week before and after administering ivermectin,and that it should be given at bedtime to avoid drug interactions.